Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference

Core Insights - Graviton Bioscience Corporation is focused on developing selective ROCK2 inhibitors for various disorders, including metabolic, inflammatory, fibrotic, and central nervous system conditions [3] - The company will present its obesity research program and ROCK2 inhibitor development during a fireside chat at the 8th Annual Evercore HealthCONx Conference on December 2, 2025 [1][2] Company Overview - Graviton Bioscience is a clinical-stage biotechnology company dedicated to creating therapeutics targeting diseases where ROCK2 plays a significant role [3] - The company's first drug candidate, GV101, is currently in clinical studies, with additional assets progressing through preclinical stages [3] - Dr. Samuel Waksal, the CEO, has a notable background, having founded and led multiple pharmaceutical companies, including Kadmon Pharmaceuticals and ImClone Systems [3] Product Development - GV101 is a highly selective ROCK2 inhibitor that has shown efficacy in preclinical obesity models, reducing lipid droplets in both mouse and human adipocytes [5] - The ROCK2 inhibitors developed by Graviton are reported to decrease weight similarly to GLP-1 receptor agonists while preserving relative lean mass [5] - Clinical significance of GV101 includes promoting healthier weight loss through sustained fat loss while maintaining muscle mass [5]